Miltefosine: a promising agent for leishmaniasis
DOI:
https://doi.org/10.66344/jpad.28.1.2018.1201References
Azzouz, S, Maach M, Garcia RG, Osuna A. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin Pharmacol Toxicol. 2005;96(1):60-65.
Vakil N H, Fujinami N, Shah PJ. Pharmacotherapy for Leishmaniasis in the United States: Focus on miltefosine. Pharmacotherapy. 2015;35(5):536-45.
Tuon FF, Amato V S, Graf ME, Siqueira AM, Nicodemo AC, AmatoNeto V. Treatment of New World cutaneous leishmaniasis- a systematic review with a meta-analysis. Int J Dermatol. 2008;47:109-124.
Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Antimicrob Agents Chemother. 2012;67:2576-97.
Pinto-Martinez A K, Rodriguez-Durán J, Serrano-Martin X, Hernandez-Rodriguez V, Benaim G. Mechanism of action of miltefosine on Leishmania donovani involves the impairment of acidocalcisome function and the activation of the sphingosine-dependent plasma membrane Ca2+ channel. Antimicrob Agents Chemother. 2018;62(1):e01614-17.
David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther. 2009;22:491-502.
Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg. 2006;100(1):S17-S20.
Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health. 2001;6(2):928-34.
Fischer C, Voss A, Engel J. Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. Med Microbiol Immunol. 2001;190(1-2):85-7.
Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 1998;352(9143):1821-3.
Rubiano LC, Miranda MC, Muvdi A, Montero LM, RodrÃguez-Barraquer I, Garcerant D et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis. 2012;205:684-92.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
